Cargando…

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. This study was aimed at evaluating the efficacy of AR-42 (formerly OSU-HDAC42), a novel histone deacetylase (HDAC) inhibitor currently in clinical trials, in suppressing tumor growth and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henderson, Sally E., Ding, Li-Yun, Mo, Xiaokui, Bekaii-Saab, Tanios, Kulp, Samuel K., Chen, Ching-Shih, Huang, Po-Hsien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126135/ https://www.ncbi.nlm.nih.gov/pubmed/27889645 http://dx.doi.org/10.1016/j.neo.2016.10.003

Ejemplares similares

Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
por: Chua, Ming Jang, et al.
Publicado: (2021)

Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways
por: Chen, Yi-Jin, et al.
Publicado: (2017)

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
por: Lucas, David M., et al.
Publicado: (2010)

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
por: Murahari, Sridhar, et al.
Publicado: (2017)

The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors
por: Elshafae, Said M., et al.
Publicado: (2021)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
por: Wu, Christina, et al.
Publicado: (2012)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells
por: Mates, Jessica M., et al.
Publicado: (2015)

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
por: Welling, D. Bradley, et al.
Publicado: (2021)

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
por: Ahn, Daniel H., et al.
Publicado: (2018)

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?
por: Martin, Ludmila Katherine, et al.
Publicado: (2012)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

Response to Drs Von Hoff and Renschler
por: Ahn, Daniel H., et al.
Publicado: (2017)

Identifying and targeting cancer stem cells in the treatment of gastric cancer
por: Bekaii‐Saab, Tanios, et al.
Publicado: (2017)

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
por: Guzman, Monica L., et al.
Publicado: (2014)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies
por: Sonbol, Mohamad B., et al.
Publicado: (2019)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report
por: So, Brian J, et al.
Publicado: (2008)

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
por: Liva, Sophia G, et al.
Publicado: (2020)

The histone deacetylase Hos2 forms an Hsp42-dependent cytoplasmic granule in quiescent yeast cells
por: Liu, I-Chun, et al.
Publicado: (2012)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
por: Kaumaya, Pravin T. P., et al.
Publicado: (2020)

Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells
por: Lin, Peng-Chan, et al.
Publicado: (2018)

Pitfalls in AR42J-model of cerulein-induced acute pancreatitis
por: Hollenbach, Marcus, et al.
Publicado: (2021)

Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies
por: Lawal, Bashir, et al.
Publicado: (2021)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_at67k8q109k7knmfid48etsn9q